Jorda Radek
Journals
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Expert Opinion on Therapeutic Patents.
2023,
33(2),
67-87,
ISSN: 1354-3776,
PMID: 36975020,
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines.
Investigational New Drugs.
2023,
41(2),
210-219,
ISSN: 0167-6997,
PMID: 36913160,